Summary of Key Points from the Conference Call Company Overview - **Company**: 微芯生物 (Microchip Biotech) - **Focus Areas**: Oncology, metabolic diseases, autoimmune diseases, neurodegenerative diseases, and antiviral fields [5][6][19] Clinical Trials and Research Updates - **Sida Benamine (西达本胺)**: - Ongoing international Phase III clinical trial for first-line treatment of melanoma in combination with Opdivo, with primary endpoint data expected in 2026 [2][3][21] - Phase III trial for triple therapy in late-line colorectal cancer is also in progress [2][3] - Significant efficacy observed in recurrent resistant NKT cell treatment, with a patient benefit rate of 97.6% and a one-year sustained remission rate of 96% [2][7] - Response rate for advanced progressive urothelial carcinoma improved to 44%, with progression-free survival (PFS) extended to 7 months [2][8] - **Ronin (罗尼)**: - Completed enrollment for Phase III clinical trial in ovarian cancer and initiated a Phase II trial combining with Nivolumab and Gemcitabine [12] - Expected to provide better benefits for highly fibrotic tumors like pancreatic cancer [12] - **Small Molecule PD-1 Inhibitor (23,546)**: - Strong tissue penetration and blood-brain barrier permeability, with ongoing Phase I trials in China and plans for FDA submission this year [2][13] - **Multi-target Kinase (231,295)**: - Good application prospects for brain tumors and brain metastases, with plans for FDA submission in Q3 [2][14] - **Sitagliptin (西格列汀钠)**: - Used for Type 2 diabetes, showing clinical benefits in metabolic syndrome and related comorbidities [4][15][17] - Positioned as a foundational drug for managing metabolic diseases [16][17] Strategic Focus and Development - **Research Strategy**: - Focus on developing drugs at different levels, including original, follow-up, and lifecycle management [5] - Emphasis on addressing unmet clinical needs in oncology and metabolic diseases [5] - **Collaboration and Innovation**: - Collaborating with other institutions to develop new drug forms, including ADCs and nucleic acid vaccines [20] - Utilizing AI to enhance early-stage research and clinical development processes [19] Market Potential and Future Outlook - **Market Strategy**: - Continuous exploration of market resources for existing products while targeting significant unmet clinical needs [5] - Anticipation of data readouts and market strategies based on ongoing clinical trials [2][21] - **Regulatory Submissions**: - Plans for FDA submissions for several candidates, including 23,546 and 231,295, highlighting the company's commitment to advancing its pipeline [13][14] Additional Insights - **Take2**: - Recently completed Phase I trials, with Phase II data expected by the end of the year, showing promising PD data compared to competitors [25] - **Clinical Efficacy**: - Emphasis on the unique mechanisms of action for new small molecules, including oral PD-1 inhibitors, which may offer advantages over traditional therapies [23][24] This summary encapsulates the key developments, strategic focus, and future outlook for 微芯生物, highlighting its commitment to innovation and addressing unmet medical needs in various therapeutic areas.

医药板块近期持续上行，6月首个交易日，医疗保健、制药等板块再度走强。 A股相关ETF中，科创医药指数ETF（588700）截至发稿涨超2%，盘中换手率超6%，溢折率0.12%， 溢价交易明显。成分股中，微芯生物涨超14%，神州细胞、三生国健、华熙生物等多股涨幅在8%以 上。 科创医药指数ETF（588700）紧密跟踪上证科创板生物医药指数，上证科创板生物医药指数从科创板市 场中选取50只市值较大的生物医药、生物医学工程、生物农业、生物质能、其他生物业等领域上市公司 证券作为指数样本，反映科创板市场代表性生物医药产业上市公司证券的整体表现。该ETF配备了2只 场外联接基金（A类：021060；C类：021061）。 实际上，在刚刚过去的5月份，医药板块表现强势。Wind数据显示，以申万一级行业为例，5月份，申 万医药生物指数单月涨6.42%，仅次于环保（6.83%）。 而消息面上，在5月最后一周，诸多创新药顺利获批，5月29日一日内获批创新药11款，创新药进入兑现 收获期。 国金证券指出，上周国家药监局批准11款全新创新药的上市申请，另外还有2款创新药拟纳入优先审 评，新品种密集获批有望赶上今年医保谈判放量，为 ...

Group 1 - The core viewpoint highlights the positive market reaction to the collaboration between Bristol-Myers Squibb and BioNTech regarding the new cancer drug BNT327, with milestone payments potentially reaching $11.1 billion, which has boosted the performance of innovative drug concept stocks [1] - The performance of the Kexin Biopharmaceutical ETF (588250.SH) increased by 1.23%, with its associated index Kexin Biopharmaceutical (000683.SH) rising by 0.96%, indicating a favorable market sentiment towards the biopharmaceutical sector [1] - Notable increases in major component stocks include Microchip Biotech rising by 9.44%, Huaxi Biotech by 7.63%, and Rongchang Biotech by 4.92%, reflecting strong investor interest in innovative drug companies [1] Group 2 - Guosen Securities reported significant advancements in domestic innovative drugs, particularly focusing on bispecific antibodies and ADC technologies, with promising clinical data from Innovent Biologics and Mingji Biotech in pancreatic cancer treatments [2] - Shenwan Hongyuan highlighted Huaxi Biotech as a key player in the recombinant collagen market, benefiting from the domestic beauty trend and strong brand recognition, suggesting potential for consumer recovery [2] - Both research institutions' insights align with the performance of innovative drug and medical beauty leading companies within the Kexin Biopharmaceutical ETF [2]

Group 1 - The A-share market saw a positive trend with the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index rising by 1.95% as of the report time [1] - The Science and Technology Innovation Medicine Index ETF (588700) increased by 2.18%, with a turnover rate of 8.76% and a transaction volume exceeding 23.75 million [1] - Among the constituent stocks, Yifang Biotechnology-U surged over 12%, Borui Pharmaceutical rose over 8%, and Microchip Biotech increased over 7% [1] Group 2 - According to Industrial Securities, the innovative drug sector's prosperity is expected to be sustainable, with "innovation + internationalization" remaining the core direction of the pharmaceutical sector [2] - The report highlights that the innovative drug industry chain's fundamentals are beginning to improve, with overseas orders and performance starting to recover [2] - The demand in the domestic market is anticipated to rebound by 2025, with potential recovery in the consumption medical field, including medical services and OTC traditional Chinese medicine [2]

Group 1 - The company issued convertible bonds totaling RMB 500 million, with a maturity of six years from July 5, 2022, to July 4, 2028 [2] - The initial conversion price for the bonds was set at RMB 25.36 per share, effective from January 11, 2023 [2] - The conversion price was adjusted to RMB 25.26 per share starting June 4, 2024, due to a reduction in the company's total share capital [3] Group 2 - The company has a provision for downward adjustment of the conversion price if the stock price falls below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [4] - If the conditions for price adjustment are met, the board will propose a new conversion price to be approved by shareholders, requiring a two-thirds majority [4] - The company will announce any adjustments to the conversion price through the Shanghai Stock Exchange and will resume conversion applications at the adjusted price [5][6] Group 3 - From May 15 to May 28, 2025, the company's stock price has been below RMB 21.47, which is 85% of the current conversion price, indicating a potential trigger for price adjustment [6] - If the stock price continues to meet the adjustment criteria for 20 consecutive trading days, the company will convene a board meeting to decide on the adjustment [6]

| 证券代码：688321 | 证券简称：微芯生物 | 公告编号： 2025-036 | | --- | --- | --- | | 转债代码：118012 | 转债简称：微芯转债 | | 深圳微芯生物科技股份有限公司 关于 "微芯转债"预计满足转股价格修正条件的提 示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、可转债发行上市概况 经中国证券监督管理委员会"证监许可[2022]1234 号"文同意 注册，深圳微芯生物科技股份有限公司（以下简称"公司"）于 2022 年 7 月 5 日向不特定对象发行可转换公司债券 500.00 万张， 每张面值为人民币 100 元，发行总额为人民币 50,000.00 万元（人 民币伍亿元整），发行的可转换公司债券的期限为自发行之日起六年， 即自 2022 年 7 月 5 日至 2028 年 7 月 4 日。 经上海证券交易所自律监管决定书〔2022〕195 号文同意，公 司发行的 50,000.00 万元可转换公司债券已于 2022 年 7 月 28 日起 在上海证券交易 ...

Group 1 - The A-share market showed mixed performance on May 28, with the Sci-Tech Innovation Pharmaceutical Index ETF (588700) down 0.21% and a trading volume exceeding 8 million yuan [1] - The Sci-Tech Innovation Pharmaceutical Index ETF closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index, which includes 50 large-cap companies in biopharmaceuticals, biomedical engineering, and related sectors [1] - Recent data from the American Society of Clinical Oncology (ASCO) annual meeting highlighted that Chinese experts had a record number of presentations, with 71 original research results showcased, indicating a strong international presence for Chinese innovative drugs [1] Group 2 - CITIC Securities expressed strong confidence in a reversal trend for the pharmaceutical sector in 2025, emphasizing innovative drugs and the recovery of left-behind sectors as key investment opportunities [2] - Zhongtai Securities noted that the Chinese innovative drug industry is transitioning from a phase of capital bubble to a stage of genuine achievements, with increasing recognition from multinational corporations [2] - The recommendation includes actively embracing the pharmaceutical sector and exploring opportunities in AI healthcare and related fields, as well as sub-industries and individual stocks experiencing recovery [2]

Meeting Overview - The shareholder meeting of Shenzhen Microchip Biotech Co., Ltd. was held on May 20, 2025, at the Zhigu Industrial Park in Nanshan, Shenzhen [1] - A total of 118 ordinary shareholders attended the meeting, representing 105,345,510 voting rights, which accounts for 25.83% of the company's total voting rights [1] Voting Results - All proposed resolutions were approved during the meeting, with significant support from ordinary shareholders [1][2] - The voting results for the resolutions included: - Resolution 1: 104,570,216 votes in favor (99.26%), 702,913 abstentions (0.67%), and 72,381 against (0.07%) [2] - Resolution 2: 103,324,534 votes in favor (98.08%), 1,941,495 against (1.84%), and 79,481 abstentions (0.08%) [2] - Resolution 3: 104,507,771 votes in favor (99.20%), 610,158 against (0.58%), and 227,581 abstentions (0.22%) [2] - Resolution 4: 104,611,364 votes in favor (99.30%), 654,665 against (0.62%), and 79,481 abstentions (0.08%) [2] Legal Compliance - The meeting was conducted in accordance with the Company Law and the company's articles of association, ensuring that all procedures were legally valid [1][6][7] - The presence of legal representatives confirmed the legality of the meeting and the validity of the voting results [6][7]

SHANGHA 88 Yin Chena Road Mi anahai 200120 PR Chir 上海市通力律师事务所关于深圳微芯生物科技股份有限公司 2024 年年度股东大会的法律意见书 致:深圳微芯生物科技股份有限公司 上海市通力律师事务所(以下简称"本所")接受深圳微芯生物科技股份有限公司(以下 简称"公司")的委托,指派本所郭询律师、何馨悦律师(以下简称"本所律师")根据《中华 人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规则》等法律法规和规范 性文件(以下统称"法律法规")及《深圳微芯生物科技股份有限公司章程》(以下简称"公司 章程")的规定就公司 2024 年年度股东大会(以下简称"本次股东大会")相关事宜出具法 律意见。 本所律师已经对公司提供的与本次股东大会有关的法律文件及其他文件、资料予以了 核查、验证。在进行核查验证过程中,公司已向本所保证,公司提供予本所之文件中的所有 签署、盖章及印章都是真实的,所有作为正本提交给本所的文件都是真实、准确、完整和有 效的,且文件材料为副本或复印件的,其与原件一致和相符。 在本法律意见书中,本所仅对本次股东大会召集和召开的程序、出席本次股 ...

深圳微芯生物科技股份有限公司 2024年度股东大会决议公告 证券代码：688321 证券简称：微芯生物 公告编号：2025-035 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 20 日 （二） 股东大会召开的地点：深圳市南山区西丽街道智谷产业园 B 栋 22 楼董事 会会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 118 | | --- | --- | | 普通股股东人数 | 118 | | 2、出席会议的股东所持有的表决权数量 | 105,345,510 | | 普通股股东所持有表决权数量 | 105,345,510 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 25.8328 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 25.832 ...